Parag Sanghvi, M.D., M..S.P.H.
NPI 1801005152 · Radiation Oncology Physician · San Diego, CA
Enrolled with Medicare as Practitioner - Radiation Oncology · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1801005152
- Entity type
- Individual
- Primary specialty
- Radiation Oncology PhysicianAllopathic & Osteopathic Physicians
- Credential
- M.D., M..S.P.H.
- Sex
- Male
- Sole proprietor
- No
- License
- A105184 (CA)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure28% of score
19 yrs in NPPES registry
- Profile completeness28% of score
100% of core fields populated
- Practice footprint17% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)28% of score
1,921 Medicare services, 2024 (ranked within specialty)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our methodology.
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Ct Guidance for Insertion of Radiation Therapy Fields77014 | 642 | $46 |
| Calculation of Radiation Therapy Dose77300 | 322 | $34 |
| Radiation Treatment Management, 5 Treatment Sessions77427 | 160 | $198 |
| Design and Construction of Complex Radiation Treatment Device77334 | 133 | $63 |
| Stereoscopic X-Ray Guidance for Localization of Target Volume for the Delivery of Radiation TherapyG6002 | 84 | $21 |
| Established Patient Office Or Other Outpatient Visit With High Level of Medical Decision Making, If Using Time, 40 Minutes Or More99215 | 79 | $147 |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 2 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Lidocaine Hclbrand: Lidocaine Hcl Viscous | 19 | 15 |
| Mometasone Furoate | 12 | 12 |
Medicare Part D only. These counts cover prescriptions paid through Medicare Part D in 2024 — they do notinclude cash-pay, commercial-insurance, Medicaid, or Part B–administered drugs, and badly undercount high cash-pay categories (e.g. GLP-1 weight-loss, testosterone, and ED medications). Any drug with 10 or fewer claims is omitted by CMS, and beneficiary counts under 11 are suppressed — so a missing drug means no Part D record, never zero. This is a factual claims summary, not an endorsement, not medical advice, and not a consumer report. Source: CMS Medicare Part D Prescribers — by Provider and Drug.
Practice location
Mailing address
Registry dates
- Enumerated
- 2007-05-22
- Last updated
- 2023-03-07
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.